{"title":"Advancing forced degradation studies: Design of experiments for enhanced structure-function relationship analysis in biotherapeutics","authors":"Klaus Kronsbein , Verena Nold , Armin Böhrer , Beate Presser , Tanja Gaissmaier , Katharina Schindowski , Boris Mizaikoff , Florian Krattenmacher","doi":"10.1016/j.ejpb.2025.114787","DOIUrl":null,"url":null,"abstract":"<div><div>Understanding the relationship between structure and function is crucial in drug development. Recombinant proteins present unique challenges when establishing structure–function relationships (SFR) due to the extensive options for potential modifications across numerous residues. Even simple stress studies lack degradation selectivity as they lead to multiple, simultaneous modifications. Co-occurring modifications at amino acid residues make direct correlations with a specific stressor and resolving the causal impact on functionality difficult. The introduction of more variance into the data set would reduce the correlation structure. In this study, we demonstrate the feasibility and benefits of a multifactorial design approach for SFR establishment. Design of experiments (DoE) allows for the parallel investigation of stress factors via combined experiments, resulting in a higher variance of stress conditions and consequently a broader variation in degradation. This approach enables a more insightful correlation analysis along with model-based data evaluation strategies, thereby facilitating significantly improved data interpretation results during SFR studies.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"214 ","pages":"Article 114787"},"PeriodicalIF":4.3000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S093964112500164X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Understanding the relationship between structure and function is crucial in drug development. Recombinant proteins present unique challenges when establishing structure–function relationships (SFR) due to the extensive options for potential modifications across numerous residues. Even simple stress studies lack degradation selectivity as they lead to multiple, simultaneous modifications. Co-occurring modifications at amino acid residues make direct correlations with a specific stressor and resolving the causal impact on functionality difficult. The introduction of more variance into the data set would reduce the correlation structure. In this study, we demonstrate the feasibility and benefits of a multifactorial design approach for SFR establishment. Design of experiments (DoE) allows for the parallel investigation of stress factors via combined experiments, resulting in a higher variance of stress conditions and consequently a broader variation in degradation. This approach enables a more insightful correlation analysis along with model-based data evaluation strategies, thereby facilitating significantly improved data interpretation results during SFR studies.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.